Skip to content
PeptideAgent

Compounding pharmacies in Maine

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Maine Board of Pharmacy (Office of Professional and Occupational Regulation) regulates compounding pharmacies in Maine. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Maine at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Maine

No verified compounding pharmacies serving Maine are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Maine

The Maine Board of Pharmacy licenses pharmacists and pharmacies under the Maine Pharmacy Act, 32 M.R.S. chapter 117, and adopts practice rules in chapter 02-392 of the Code of Maine Rules. Section 13751, subsection 1, requires every pharmacy to obtain an annual Board license, and subsection 2 lists the classifications, including mail order prescription pharmacy. Board rules chapter 11, section 1 applies that classification to a pharmacy that dispenses prescription drugs by mail or carrier from a facility outside Maine to a patient who lives in Maine; the applicant must file a copy of its most recent inspection report from its home state and keep a toll-free line to a pharmacist open at least 40 hours a week. Inside Maine, a sterile compounding pharmacy needs a separate license under Board rules chapter 37, and non-sterile compounding must follow USP chapter 795 under Board rules chapter 13, section 7. A 2013 bill that would have required out-of-state pharmacies that compound drugs for Maine patients to hold their own annual Maine license (LD 1315, 126th Legislature) was vetoed, and the veto was sustained on June 26, 2013; section 13751 as checked on 2026-09-22 contains no compounding-specific license for out-of-state pharmacies, and the scope section of Board rules chapter 37 does not address pharmacies located outside Maine. Maine has no state bulks list; eligibility of a peptide for compounding follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). [1] [3] [4] [5] [6] [7] [8] [9]

Compounded GLP-1 access in Maine

Because Maine requires a pharmacy that mails prescriptions to Maine patients from outside the state to hold a mail order prescription pharmacy license, a telehealth GLP-1 program that ships a compounded vial into Maine from a pharmacy without that license is not lawful in the state. Maine patients should also confirm that the prescriber holds a full Maine license, since unregistered out-of-state physicians may only consult. [2] [4] [6] [12]

Research use only sellers in Maine

The Maine Pharmacy Act limits dispensing of prescription drugs to licensed pharmacies and practitioners, so an online seller of "research use only" injectable peptides to Maine consumers is not a lawful dispenser in Maine. [3] [13]

How to check a compounding pharmacy in Maine

  1. Search the Maine Board of Pharmacy (Office of Professional and Occupational Regulation) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Maine requires before it ships to you. [1] [3] [4] [5] [6] [7] [8] [9]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Maine. [3] [13]

Common questions in Maine

Can an out-of-state pharmacy ship compounded peptides to me in Maine?

Only if it holds a Maine mail order prescription pharmacy license. The Maine Pharmacy Act and Board rules chapter 11 require a pharmacy that mails prescriptions to Maine patients from outside the state to be licensed and to file its latest home-state inspection report. A 2013 bill that would have added a separate license for out-of-state compounders was vetoed, so the mail order license is the Maine requirement. Check the pharmacy in the state license lookup before ordering. [1] [4] [5] [6]

Can a Maine pharmacy compound BPC-157 or other unapproved peptides?

No, not from bulk today. BPC-157 is not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk. State boards cannot authorize what federal law does not. Peptides still in FDA Category 2 cannot be compounded either. [9] [10] [11]

All peptide legal questions for Maine

Sources

  1. [1]Maine Board of Pharmacy (Office of Professional and Occupational Regulation)
  2. [2]Maine Revised Statutes Title 32, section 3300-D, Interstate practice of telehealth
  3. [3]Maine Revised Statutes Title 32, chapter 117, Maine Pharmacy Act
  4. [4]Maine Revised Statutes Title 32, section 13751, Registration and licensure of drug outlets
  5. [5]Maine LD 1315 (126th Legislature), An Act To Ensure the Safety of Compounded Drugs: status page (vetoed June 21, 2013; veto sustained June 26, 2013)
  6. [6]Code of Maine Rules 02-392, chapter 11, section 1, Mail order prescription pharmacy
  7. [7]Code of Maine Rules 02-392, chapter 37, Licensure of sterile compounding pharmacies
  8. [8]Code of Maine Rules 02-392, chapter 13, section 7, Compounding (non-sterile, USP chapter 795)
  9. [9]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  10. [10]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA